

Mr. Henning Gädeke, Chair of the Global Health EDCTP3 Joint Undertaking Governing Board
c/o Dr. Michael Makanga, Executive Director, Global Health EDCTP3 Joint Undertaking
Global Health EDCTP3 Joint Undertaking
56 – 60 Avenue de la Toison d’Or
1060 Brussels
Belgium

1 September 2025

Letter of endorsement

Dear Sir/Madam,

On behalf of McMaster University, 1280 Main St. West, Hamilton, ON, Canada and in accordance with Council Regulation (EU) No 2085/2021 of 19th November 2021 establishing the joint undertakings under Horizon Europe and specifically Article 9 therein, I hereby apply to become a contributing partner to the Global Health EDCTP3 Joint Undertaking (Global Health EDCTP3 JU).

McMaster University researchers are engaged in the research and development of aerosol vaccines against tuberculosis and COVID-19. The Global Health EDCTP3 JU recently announced a call entitled “Global collaboration action for the development of vaccines for reducing the disease burden of Tuberculosis in sub-Saharan Africa”. McMaster has applied to this specific call.

Additionally, McMaster University would like to contribute to the Global Health EDCTP3 JU’s initiative described above through in-kind contributions. These contributions include the work packages #3 and #4.

We estimate the total value of this contribution to be € 3,186,650, including the costs for the cGMP production of the candidate AdHu5Ag85A TB vaccine, its quality control, batch testing, and labelling (amounting € 1,225,000). Other in-kind contributions (amount=€261,900) are meant for GFP for Ad5 Immunoassay, support/scholarship of 1 MSc student for 2 years, data management costs and training costs of students (1 post-doctoral and 2 PhD students from Africa). In addition, McMaster will engage 10 senior and junior scientists who will dedicate equivalent effort to 187 person-months during the 5-year life span of the project (amounting to € 1,699,750).

We confirm the following:

1. We will comply with the Horizon Europe Regulation (EU) No 2021/695; Council Regulation (EU) No 2085/2021 establishing the joint undertakings under Horizon Europe; the Model Grant Agreement for Horizon Europe and applicable Global Health EDCTP3 JU rules, including

the relevant work programs and, in particular, the call conditions therein.

2. We will keep all information received in the context of our involvement as a contributing partner to Global Health EDCTP3 JU confidential. This confidentiality obligation applies, but is not limited to, the areas of Global Health EDCTP3 JU call topic preparation and publication, proposal submission and evaluation, and consortium formation. We further understand that this obligation strictly prohibits the release of confidential information to any legal entity save where specifically authorised by Global Health EDCTP3 JU. Internal dissemination of information within our organisation will be done based on the “need-to-know” principle.
3. We are confident of our ability to fulfil the above commitments and further confirm our understanding that Global Health EDCTP3 JU will allocate resources to the above topic based on these commitments.
4. The value of our contribution will be based on costs calculated in accordance with Article 6 of the Horizon Europe Model Grant Agreement.
5. We accept that additional modalities regarding the provision of our contribution may be defined in subsequent agreements or documents, such as a funding agreement and topic text.

Yours faithfully,



Dawit Wolday MD, PhD

(Principal Investigator for McMaster Team)

Associate Professor

Department of Biochemistry & Biomedical Sciences

Michael G. DeGroote Institute for Infectious Diseases Research (IIDR)

McMaster Immunology Research Center (MIRC)

Faculty of Health Sciences

📍 *location: 5030 MDCL (Office), 4084 MDCL (Lab), 1280 Main St. West, Hamilton, ON L8S 4L8*

📞 *phone: (905) 525-9140 x 20818*

✉ *email: woldayd@mcmaster.ca*